The invention relates to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain, and in particular to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain using one or more biomarkers.

The invention relates to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain, and in particular to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain using one or more biomarkers.

A sample dispensing mechanism configured to dispense a sample and a reagent to the reaction vessel at a first dispensing position and the reaction cell positioned at a second dispensing position; a second reagent vessel disposed on a track of the sample dispensing mechanism; and a control unit configured to control the sample dispensing mechanism, in which the control unit is configured to, based on information on presence or absence of incubation of an analysis item, control the sample dispensing mechanism to dispense a sample and a reagent to the reaction vessel positioned at the first dispensing position in a case where the incubation is not required by the analysis item, and control the sample dispensing mechanism to dispense a sample to the reaction cell positioned at the second dispensing position in a case where the incubation is required by the analysis item.

A sample dispensing mechanism configured to dispense a sample and a reagent to the reaction vessel at a first dispensing position and the reaction cell positioned at a second dispensing position; a second reagent vessel disposed on a track of the sample dispensing mechanism; and a control unit configured to control the sample dispensing mechanism, in which the control unit is configured to, based on information on presence or absence of incubation of an analysis item, control the sample dispensing mechanism to dispense a sample and a reagent to the reaction vessel positioned at the first dispensing position in a case where the incubation is not required by the analysis item, and control the sample dispensing mechanism to dispense a sample to the reaction cell positioned at the second dispensing position in a case where the incubation is required by the analysis item.

Disclosed herein are methods for making a transcriptome-wide expression profile of a biological sample and identifying biomarkers that can be used to diagnose, monitor the onset, monitor the progression, and assess the recovery of a disease in a subject. The biomarkers can also be used to establish and evaluate treatment regimens.

The present disclosure provides a method and system for estimating the clinical responsiveness of a patient to a dose of a plasminogen activating agent to treat a thrombosis, comprising determining a concentration of α2-antiplasmin in a blood sample of the patient, determining a concentration of activated fibrinolysis inhibitor (“TAFI”) in the blood sample, determining a concentration of plasminogen activator Inhibitor 1 (“PAI-1”) in the blood sample, computing a clot lysis time (“CLT”) based on the concentrations of a2-antiplasmin, TAFI and PAI-1 using the equation CLT=−2,813.6+31.1*a2-antiplasmin (percent activity)+31.1*TAFI (percent activity)+1.49 PAI-1 (ug/L), and determining that the patient is at increased risk of hemorrhage when the computed CLT is less than a first predetermined cutoff time.

The present disclosure provides a method and system for estimating the clinical responsiveness of a patient to a dose of a plasminogen activating agent to treat a thrombosis, comprising determining a concentration of α2-antiplasmin in a blood sample of the patient, determining a concentration of activated fibrinolysis inhibitor (“TAFI”) in the blood sample, determining a concentration of plasminogen activator Inhibitor 1 (“PAI-1”) in the blood sample, computing a clot lysis time (“CLT”) based on the concentrations of a2-antiplasmin, TAFI and PAI-1 using the equation CLT=−2,813.6+31.1*a2-antiplasmin (percent activity)+31.1*TAFI (percent activity)+1.49 PAI-1 (ug/L), and determining that the patient is at increased risk of hemorrhage when the computed CLT is less than a first predetermined cutoff time.

The present invention related to a method for detecting a history of exposure to a chemical(s) comprising measuring the concentration of thrombomodulin in a sample isolated from a subject, and determining whether the concentration of thrombomodulin is altered compared to control reference levels.

The present invention related to a method for detecting a history of exposure to a chemical(s) comprising measuring the concentration of thrombomodulin in a sample isolated from a subject, and determining whether the concentration of thrombomodulin is altered compared to control reference levels.

The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.